CN104487425B - 治疗细菌性疾病的嘧啶衍生物 - Google Patents

治疗细菌性疾病的嘧啶衍生物 Download PDF

Info

Publication number
CN104487425B
CN104487425B CN201380022591.6A CN201380022591A CN104487425B CN 104487425 B CN104487425 B CN 104487425B CN 201380022591 A CN201380022591 A CN 201380022591A CN 104487425 B CN104487425 B CN 104487425B
Authority
CN
China
Prior art keywords
compound
mmol
compounds
alkyl
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380022591.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104487425A (zh
Inventor
J-F.邦范蒂
P.马勒
F.M.M.多布勒特
J.M.C.福廷
N.洛尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen R&D Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland ULC filed Critical Janssen R&D Ireland ULC
Publication of CN104487425A publication Critical patent/CN104487425A/zh
Application granted granted Critical
Publication of CN104487425B publication Critical patent/CN104487425B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380022591.6A 2012-04-30 2013-04-30 治疗细菌性疾病的嘧啶衍生物 Active CN104487425B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12166140 2012-04-30
EP12166140.9 2012-04-30
PCT/EP2013/058980 WO2013164337A1 (en) 2012-04-30 2013-04-30 New compounds and new use

Publications (2)

Publication Number Publication Date
CN104487425A CN104487425A (zh) 2015-04-01
CN104487425B true CN104487425B (zh) 2016-09-14

Family

ID=48430690

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380022591.6A Active CN104487425B (zh) 2012-04-30 2013-04-30 治疗细菌性疾病的嘧啶衍生物

Country Status (16)

Country Link
US (2) US9725432B2 (cg-RX-API-DMAC10.html)
EP (1) EP2938599B1 (cg-RX-API-DMAC10.html)
JP (2) JP6349303B2 (cg-RX-API-DMAC10.html)
KR (1) KR102186851B1 (cg-RX-API-DMAC10.html)
CN (1) CN104487425B (cg-RX-API-DMAC10.html)
AR (1) AR090880A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013255843B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014026776B1 (cg-RX-API-DMAC10.html)
CA (1) CA2868930C (cg-RX-API-DMAC10.html)
EA (1) EA030899B1 (cg-RX-API-DMAC10.html)
ES (1) ES2676189T3 (cg-RX-API-DMAC10.html)
IN (1) IN2014MN02363A (cg-RX-API-DMAC10.html)
MX (1) MX358189B (cg-RX-API-DMAC10.html)
NZ (2) NZ724424A (cg-RX-API-DMAC10.html)
TW (1) TWI598099B (cg-RX-API-DMAC10.html)
WO (1) WO2013164337A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090880A1 (es) * 2012-04-30 2014-12-10 Janssen R & D Ireland Derivados de pirimidina
WO2019121352A1 (en) * 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2011060976A1 (en) * 2009-11-20 2011-05-26 Universite De Liege Tryptamine-derived compounds as antibacterial agents
WO2011061214A1 (en) * 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
WO2011073378A1 (en) * 2009-12-18 2011-06-23 Basilea Pharmaceutica Ag Tricyclic antibiotics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
DE102004003493A1 (de) 2004-01-23 2005-08-11 Bayer Cropscience Ag 5-Phenylpyrimidine
EP1871762A2 (en) * 2005-04-18 2008-01-02 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
AU2009208712B2 (en) * 2008-02-01 2013-03-14 Orchid Chemicals & Pharmaceuticals Limited Novel heterocycles
AR090880A1 (es) * 2012-04-30 2014-12-10 Janssen R & D Ireland Derivados de pirimidina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2011061214A1 (en) * 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
WO2011060976A1 (en) * 2009-11-20 2011-05-26 Universite De Liege Tryptamine-derived compounds as antibacterial agents
WO2011073378A1 (en) * 2009-12-18 2011-06-23 Basilea Pharmaceutica Ag Tricyclic antibiotics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
1060376-66-0/RN;美国化学会;《STN ON THE WEB》;20081013;第4页结构式 *
1060384-06-6/RN;美国化学会;《STN ON THE WEB》;20081013;第3页结构式 *
1060386-34-6/RN;美国化学会;《STN ON THE WEB》;20081013;第2页结构式 *
1060430-47-8/RN;美国化学会;《STN ON THE WEB》;20081013;第2页结构式 *
1065610-31-2/RN;美国化学会;《STN ON THE WEB》;20081024;第1页结构式 *
1069567-76-5/RN;美国化学会;《STN ON THE WEB》;20081102;第1页结构式 *

Also Published As

Publication number Publication date
EA030899B1 (ru) 2018-10-31
EA201491992A1 (ru) 2015-02-27
WO2013164337A9 (en) 2014-09-18
CN104487425A (zh) 2015-04-01
EP2938599B1 (en) 2018-04-11
BR112014026776B1 (pt) 2020-03-17
JP2018135338A (ja) 2018-08-30
US20170334880A1 (en) 2017-11-23
TWI598099B (zh) 2017-09-11
JP6622839B2 (ja) 2019-12-18
AU2013255843B2 (en) 2017-11-02
EP2938599A1 (en) 2015-11-04
AR090880A1 (es) 2014-12-10
KR20150003749A (ko) 2015-01-09
AU2013255843A1 (en) 2014-10-23
ES2676189T3 (es) 2018-07-17
NZ700507A (en) 2016-09-30
US9725432B2 (en) 2017-08-08
KR102186851B1 (ko) 2020-12-07
TW201350121A (zh) 2013-12-16
NZ724424A (en) 2018-02-23
WO2013164337A1 (en) 2013-11-07
CA2868930A1 (en) 2013-11-07
JP2015515967A (ja) 2015-06-04
US10221157B2 (en) 2019-03-05
HK1208454A1 (zh) 2016-03-04
MX2014013165A (es) 2015-01-19
MX358189B (es) 2018-08-07
IN2014MN02363A (cg-RX-API-DMAC10.html) 2015-08-14
JP6349303B2 (ja) 2018-06-27
BR112014026776A2 (pt) 2017-06-27
US20150087651A1 (en) 2015-03-26
CA2868930C (en) 2023-11-28

Similar Documents

Publication Publication Date Title
JP2018519302A (ja) 抗菌化合物
EA027345B1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
WO2012054332A1 (en) Substituted hydroxamic acids and uses thereof
EA026692B1 (ru) Стимуляторы sgc
WO2010111060A1 (en) P2x3, receptor antagonists for treatment of pain
US9745282B2 (en) Indoline compounds as aldosterone synthase inhibitors
CN104781250B (zh) 新型抗细菌化合物
RU2372339C2 (ru) Замещенные триазолы в качестве блокаторов натриевых каналов
CN104981466A (zh) 新型抗细菌化合物
WO2008142550A9 (en) Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
JP6622839B2 (ja) 細菌性疾患の処置のためのピリミジン誘導体
HK1208454B (en) Pyrimidine derivatives for the treatment of bacterial diseases
KR20150099772A (ko) 항균성 화합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: IRELAND JANSSEN R + D COMPANY

Free format text: FORMER OWNER: JANSSEN R + D IRELAND

Effective date: 20150728

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150728

Address after: The Irish Village

Applicant after: Ireland Jansen scientific company

Address before: Kirk County, Ireland

Applicant before: Tibotec Pharm Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208454

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1208454

Country of ref document: HK